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protocols in the assessment of the therapeutic outcome in 
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Department of Medical, Surgical and Health Sciences, Operative Unit of Radiology, Cattinara Hospital, Italy
Abstract
Aim: To compare the signal-to-noise ratio (SNR) and effective dose at low dose (80-100 kV) contrast-enhanced computed tomography (CT) to conventional 
contrast-enhanced CT (120 kV) in the assessment of the therapeutic outcome in patients with hepatocellular carcinoma (HCC) treated by thermal ablation and/
or trans-arterial chemo-embolization (TACE).
Materials and methods: Twenty-one cirrhotic patients (15 male and 6 female, 71 years ± 15) with HCC(s) were referred to contrast-enhanced CT to assess 
therapeutic outcome after thermal ablation (n=7) or TACE (n=7) or thermal ablation and TACE (n=7). CT examination was performed at 120 kV after 370 mgI/
mL contrast injection (120 kV-370 mgI/mL) before treatment, 100 kV after 370 mgI/mL contrast injection (100 kV-370 mgI/mL) at 3 months and 100 kV after 
400 mgI/mL contrast injection (100 kV-400 mgI/mL) 6 months after treatment, and 80 kV after 400 mgI/mL contrast injection (100 kV-400 mgI/mL) at 12, 18 
and 24 months after treatment. The SNR was calculated by drawing a region-of-interest in hepatic parenchyma and abdominal fat.
Results: 120 kV-370 mgI/mL vs. 100 kV-370 mgI/mL vs. 100 kV-400 mgI/mL vs. 80 kV-400 mgI/mL did not differ in SNR (3.4 ± 1.2 vs. 2.9 ± 1.16 vs. 2.9 ± 0.5 
vs. 2.2 ± 1; ANOVA test, P=0.41) while differed in effective dose (27.9 ± 8.1 vs. 17.2 ± 4.6 vs. 19.2 ± 5.2 vs. 14 ± 5.8 mSv; ANOVA test, P=0.002). 
Conclusion: Contrast-enhanced CT at 80-100 KV after high concentration iodinated contrast media injection does not reduce SNR but provides a significant 
reduction in the effective dose in cirrhotic patients undergoing follow-up after thermal ablation and/or TACE.
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Introduction 
The assessment and monitoring of therapeutic outcome after loco-
regional treatment of hepatocellular carcinoma (HCC) in cirrhotic 
patients represents an essential item. According to the American 
Association for the Study of Liver Disease (ASL) [1] and the European 
Association for the study of the liver (EASL) [2] the modified Response 
Evaluation Criteria in Solid Tumors (mRECIST) criteria [3,4] should 
be used to assess the therapeutic outcome in HCC treated by thermal 
ablation or trans-arterial chemoembolization (TACE). mRECIST 
criteria are based on the measurement of the largest dimension of 
the enhancing tumoral tissue on arterial phase of dynamic computed 
tomography (CT) or magnetic resonance (MR) imaging [5–7].
Even though both CT and MR imaging are accepted as the imaging 
modalities to be used in the assessment of the therapeutic outcome 
in HCC according to the mRECIST criteria [3,4], CT is still the most 
employed imaging technique in the clinical practice. On the other hand 
the radiation exposure during CT studies is of concern, especially in 
patients with HCC who need a prolonged imaging follow-up for an 
accurate assessment of the therapeutic outcome after loco-regional 
treatments including thermal ablation and TACE [3,4]. In these patients, 
due to multiple CT examinations scheduled during the imaging follow-
up period, radiation dose should be kept at a minimum level provided 
that a diagnostically adequate image quality is maintained. Since the 
attenuation effect of iodinated contrast material is greater at the mean 
x-ray photon energy closer to the k-edge of iodine (33.2 KeV), low tube 
voltage (80 kVp) compared with high tube voltage acquisition (120 
kVp) determines that an higher number of x-ray photons on the lower 
end of the energy spectrum presents a photoelectric interaction with 
the K-shell electrons with a consequent higher attenuation. For these 
reasons the use of a low tube voltage allows to employ a lower amount 
of iodinated contrast material required to achieve the same degree of 
contrast enhancement [8] and without image quality degradation [9]. 
By decreasing the tube voltage, the amount of iodinated contrast 
material can be reduced. In particular, the minimal iodine (I) dose 
required to achieve an acceptable tumor-to-liver contrast-to-noise 
ratio on 80-kVp corresponds to 0.3 g I/kg or 11 g I/m2 [10], while for 
CT performed at 120 kVp the iodine dose necessary to achieve 50-HU 
hepatic enhancement on portal venous phase is 0.521 g I/kg or 18.6 g 
I/m2 [11–14].
The aim of the present study was to compare 80 kV, 100 kV and 120 
kV protocols in the assessment of the therapeutic outcome in HCC.
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Materials and methods
Patients
This was a prospective observational study which was approved by 
the IRB of our hospital with a waiver of patients’ informed consent.
Inclusion criteria were: patients with HCC diagnosis based on 
imaging criteria developed by EASL and ASL [1,2] or based on histology 
who were scheduled to undergo thermal ablation (radiofrequency or 
microwave) or TACE or thermal ablation and TACE at our institution; 
contrast-enhanced CT examination performed according the following 
four protocols employed according to the time from treatment: hepatic 
arterial phase -HAP- and late phase -LP- scan at 120 kV after 370 mgI/
mL contrast media injection (Ultravist, Iopromide 370, Bayer, Berlin) 
before treatment (120 Kv-370 mgI/mL); 100 kV after 370 mgI/ml 
contrast media injection (Ultravist, Iopromide 370, Bayer, Berlin) 3 
months after treatment (100 kV–370 mgI/mL); 100 kV after 400 mgI/
ml contrast media injection (Iomeron, Iomeprol 400, Bracco, Milan) 6 
months after treatment (100 kV–400 mgI/mL); 80 kV after 400 mgI/ml 
contrast media injection (Iomeron, Iomeprol 400, Bracco, Milan) 12, 
18 and 24 months after treatment (80 kV–400 mgI/mL); no more than 
6 months between thermal ablation and TACE. 
Initially, thirty-two patients were included over a period of 
three years. Eleven patients were excluded at the end of the study: 
in particular seven patients were not referred to the scheduled CT 
examinations during the follow-up, two patients did not undero HAP 
or LP acquisition at CT examination, and two patients had numerous 
HCCs involving the entire liver that may have changed hepatic 
hemodynamics. 
Thus the final study sample consisted of 21 patients (15 male, 6 
female; age range, 48–88 years; mean, 69 years ± 15; BMI, 20 - 25; mean, 
55.0 ± 8.4 [SD] kg). The age range of the men was 48–88 years (mean, 
67.5 years), and that of the women was 52–85 years (mean, 71.0 years). 
Thermal ablation and tace
Strategies of HCC treatment by using thermal ablation and/or 
TACE were discussed at weekly multidisciplinary meetings and were 
based on pre-procedural CT images. 
All thermal ablation procedures were performed by two radiologists 
with 8 and 10 years of experience in thermal ablation before starting 
our study. Treatments were performed with the use of local anesthesia 
and conscious analgesic sedation. Thermal ablation devices included 
commercially available internally cooled electrode systems for 
radiofrequency or microvawe antenna with generators (HS AMICA 
- HS Hospital Service, Varese, Italy). Ablative margins of at least 0.5 
cm beyond the tumor boundary were planned for all lesions, with the 
exception of sub-capsular and perivascular portions. After ablation, 
electrodes were retracted with cauterization of the electrode path to 
prevent or minimize bleeding or tumor seeding. 
All TACE were performed after femoral artery cannulation with 
a 5-French catheter to outline the anatomy, delineate the tumors, and 
identify the portal vein. The third- or fourth-order branches of feeding 
vessels supplying the HCC were catheterized with a 2.8-French or a 
2.1-French microcatheter. Then, the tumors were embolized with 
a slow fluoroscopy-guided injection of iodinated contrast material 
mixed with 100–300 µm low-compression beads impregnated with 50 
mg of doxorubicin in each vial. The first- and second-order branches of 
the right or left hepatic arteries were kept patent and documented on 
postembolization completion angiography.
CT examination
CT of the liver was performed with 256-row multi-detector row 
CT system (Brilliance iCT 256, Philips, Best, The Netherlands) before 
and 3, 6, 12, 18 and 24 months after treatment. In those patients who 
underwent to a second treatment by thermal ablation or TACE, the 
contrast-enhanced CT follow-up examination was re-scheduled at 3, 
6, 12, 18 and 24 months from the last loco-regional treatment. Each 
contrast-enhanced CT examination consisted in HAP scan (automatic 
bolus-tracking with a delay of 18 seconds after the threshold of 120 
HU had been reached in the abdominal aorta) and LP scan (3 minutes 
from the beginning of contrast injection) after the i.v. bolus injection 
of iodinated contrast material (120 mL of iodinated contrast injected at 
4 mL/sec followed by 50 mL of saline flush at 2 mL/sec) administered 
with a dual-syringe power injector (Stellant CT injector, Medrad, 
Indianola, PA) via a 20-gauge catheter inserted into an antecubital 
vein. Patients were instructed to hold their breath with tidal inspiration 
during scanning. 
Technical parameters were: detector collimation; 0.625 mm; beam 
collimation, 128 × 2 × 0.625 mm; normalized beam pitch, 0.975; z-axis 
coverage, 32–160 mm; reconstruction interval, 0.3-mm; reconstructed 
section thickness, 3 mm; automatic exposure control on the basis of 
the x-ray attenuation on antero-posterior and lateral scout images 
and the reconstruction kernel; tube current (effective mA) 280–400 
mA depending on patient size; x-ray tube rotation period, 0.4–0.27 
s; field of view, 40 cm.  Combined data from both x-ray tubes were 
reconstructed with weighted filtered back projection by using the B31f 
standard reconstruction kernel to generate standard-dose datasets (the 
standard reconstruction used at our institution).
Quantitative analysis
All quantitative analysis was performed on workstation Extended 
WorkSpace eXplore (Philips, Best, The Netherlands). One board-
certified radiologist with 11 years of experience in liver CT and blinded 
to the different protocols measured the mean attenuation of the hepatic 
parenchyma with a circular region-of-interest (ROI) cursor. 
Figure 1 shows the quantitative procedure used in the present 
study. Hepatic mean attenuation was measured in Hounsfield Units 
(HU) in three separate areas (left lobe – II segment - and anterior – V - 
and posterior - VII - segments of the right lobe) on images obtained at 
the level of the main portal vein on HAP. If one or more liver segments 
were absent due to previous resection the ROI was positioned in the 
Figure 1a – c. Hepatic mean attenuation measured through one of the three ROIs placed 
over the fifth segment of the liver and one ROI drawn in peritoneal abdominal fat adjacent 
to the liver avoiding strands. Images obtained at 80kV (a), 100kV (b), and 120 kV (c).
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adjacent inferior or superior liver segment within the same liver lobe. 
The attenuation values for each liver segment were averaged and one 
single ROI value resulted from each exam. An attempt was made to 
maintain a constant ROI area of approximately 2 cm2; the range was 
0.8–2.0 cm2. Visible blood vessels, bile ducts, parenchyma areas treated 
by ablation or TACE, and artifacts were carefully excluded from 
ROI measurements in the hepatic parenchyma. One ROI was drawn 
in peritoneal abdominal fat adjacent to the liver, avoiding possible 
strands, and the standard deviation was recorded for the calculation 
of the signal-to-noise ratio (SNR) as: Liver Mean HU/SD where SD means 
standard deviation.
Contrast-to-noise ratio (CNR) was calculated using background 
attenuation values and noise from the abdominal fat at each arterial 
level as: CNR = (HUvessel − HUliver)/[(SDfat).
Attenuation measurements were obtained at hepatic parenchyma 
and within arterial ROIs as average HU and noise (standard deviation 
in HU within an ROI) at the level of the aorta at the takeoff of the 
superior mesenteric artery. The size of the ROIs was consistent for all 
subjects (52.9 mm2 within the aorta). Reference data were obtained 
from ROIs in the surrounding musculature, either erector spinae 
muscles or gluteal muscles. 
Qualitative analysis
To compare image quality in the different protocols, two board-
certified radiologists with 22 and 11 years of experience in abdominal 
CT performed consensual visual assessments of image quality including 
the visual assessment of noise and beam hardening artifacts in one 
single reading session. They were blinded to clinical data and evaluated 
both HAP and LP images. After their independent evaluations, the 
reviewers assigned a score in consensus. Image noise was quantified 
on a 3-point scale on which a score of 3 denoted almost no or minimal 
image noise throughout the image; 2, a moderate degree of image 
noise which does not limit the assessment of the liver parenchyma in 
every segments, and 1, severe image noise that may severely hamper 
liver parenchyma assessment. Beam hardening that resulted in streak 
artifacts was rated on a 3-point scale on which a score of 3 denoted 
almost no streak artifacts throughout the image; 2, a moderate degree 
of streak artifacts; and 1, strong streak artifacts. 
All readings were performed on a Picture Archiving and 
Communications System (PACS) – integrated workstation (19-inch TFT 
display, resolution 2560 × 1600 pixels, Ebit Sanità AET, Genoa, Italy) by 
using a proprietary software package (Ebit Sanità AET, Genoa, Italy). The 
preset window level of 50 HU and width of 300 HU for 120-kVp images, 
60 HU and width of 400 HU for 100-kVp images, and level of 70 HU 
and width of 450 HU for 80-kVp images could be changed be readers. 
Estimation of radiation dose 
We recorded the volume CTDIvol for scans obtained with the three 
protocols. Calculations were performed at the operating console of 
the CT scanner. We also recorded the scan range for the liver during 
the HAP and LP and calculated the dose-length product (DLP, mGy x 
cm) for the whole length of the liver on the basis of the CTDIvol (mGy) 
and scan range (cm). We then estimated the effective radiation dose by 
using the following equation: Effective dose (mSv) = (CTDIvol × scan 
range) × 0.015 [15]. 
Statistical analysis
Statistical analysis was performed using MedCalc (Mariakerke, 
Belgium). A per-patient analysis was performed. 
For data analysis, the SNR and effective dose values measured at 
CT examinations performed at 12, 18 and 24 months after treatment 
(80kV-400 mgI/ml) were averaged in each patient.
One-way ANOVA with Scheffè correction was employed to 
determine the differences in the SNR and DLP and effective dose 
among the different CT examination protocols (120 kV–370 mgI/mL; 
100 kV – 370 mgI/mL; 100 kV – 400 mgI/mL; 80 kV–400 mgI/mL). 
For all statistical tests, a P value <0.05 was considered to indicate a 
statistically significant difference.
Results
Patients underwent only radiofrequency (n=2) or microwave (n=5) 
thermal ablation or only TACE (n=7) or thermal ablation and TACE 
(n=7). In those patients who underwent both thermal ablation and 
TACE the mean temporal range between the two procedures was mean 
± SD, 4.43 ± 1 months (range 2 – 6 months).
The number of treated HCC nodules per patient were ≤2 (diameter 
± SD, 24.23 mm ± 9.6; range 10–40 mm) treated by thermal ablation, 
2 - 10 (diameter ± SD, 30.6 mm ± 17.1; range 10–80 mm) treated by 
TACE, and 1–3 (diameter ± SD, 24.9 mm ± 12.7; range 8–70mm) 
treated by thermal ablation and TACE.
On qualitative assessment CT images were quoted with a mean 
2.5 visual score (range 2–3) without any significant difference (P=0.8) 
between the different technical protocols. Beam hardening artifacts 
were visualized only in the 80 kV protocol in all patients with a mean 
score = 2. 
Table 1 shows the results of the SNR, CNR, DLP (mGy*cm), and 
the values of effective dose (mSv) for the different CT protocols. Within 
matched comparisons by Scheffè correction the protocols 120 kV - 370 
mgI/mL vs. 100 kV - 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 
400 mgI/mL did not differ in SNR (P=0.41). 
The CNR was significantly different (P=0.03) within matched 
comparisons between the CT protocols 120 kV - 370 mgI/mL vs. 100 
kV – 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 400 mgI/mL. On 
the other hand, no significant difference was found between 120 kV - 
370 mgI/mL and 100 kV - 370 mgI/mL CT protocols (P=0.4).
The mean effective dose was significantly different (P=0.03) within 
120 kV – 
370 mgI/mL
100 kV – 
370 mgI/mL
100 kV – 
400 mgI/mL
80 kV – 
400 mgI/mL
Signal-to-noise ratio (SNR) 3.4 ± 1.2 1.9 ± 1.1 1.9 ± 0.5 2.2 ± 1
Contrast-to-noise ratio (CNR) 1.9 ± 4.12 0.42 ± 1.93 0.42 ± 1.9 0.2 ± 2.78
Dose - length product (mGy*cm) 1861 ± 543.4 1148.7 ± 309.4 1232.3 ± 353.2 936.5 ± 389.7
Effective radiation dose (mSv) 27.9 ± 8.1 17.2 ± 4.6 19.2 ± 5.2 14 ± 5.8
Values are expressed as mean ± standard deviation
Table 1. Signal - to - noise ratio for the different CT examination protocols.
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matched comparisons between the CT protocols 120 kV - 370 mgI/mL 
vs. 100 kV – 370 mgI/mL vs. 100 kV - 400 mgI/mL vs. 80 kV - 400 mgI/
mL. On the other hand, no significant difference was found between 
120 kV - 370 mgI/mL and 100 kV - 370 mgI/mL CT protocols (P=0.4).
Discussion
Currently contrast-enhanced CT is the most frequently used 
imaging modality to plan and to evaluate the therapeutic outcome 
in cirrhotic patients with HCC treated by thermal ablation or TACE. 
According to both EASL and ASL [1,2] patients treated by thermal 
ablation and TACE should undergo contrast-enhanced CT examination 
every 3-6 months to assess the therapeutic outcome. According to the 
mRECIST criteria [3,4] contrast - enhanced MR imaging has also been 
assessed as a valuable method to study patients with HCC, due to its 
inherent superior tissue contrast resolution and sensitivity for detection 
of both the lesion and associated posttreatment changes in particular 
after TACE. Anyway, lower costs and higher availability make CT the 
most used imaging technqiue for both HCC characterization and post-
treatment follow-up for response assessment.
The principal finding of the present study was that CT examination 
at 80kV or 100kV after high concentration iodinated contrast agent 
(370 mgI/mL or 400 mgI/mL) injection is feasible in patients with 
HCC treated by loco-regional therapy by keeping the image quality at 
acceptable level and by minimizing the effective dose. In our study we 
found that low kV (80-100 kV) CT protocols after high concentration 
iodinated contrast media injection (370–400 mgI/mL) present a 
similar image quality and SNR and CNR but a lower effective dose 
than conventional CT protocol (120 kV). Beside cirrhotic patients 
with an HCC treated by loco-regional therapies, also those patients 
with a limited intra-venous access, patients who can receive a limited 
iodinated contrast dose due to renal failure, patients with subtle 
attenuation differences, young patients, and small and medium-sized 
adult patients could benefit from low kV CT examination. 
The usual protocol for imaging cirrhotic patients with HCC who 
underwent loco-regional treatment consists in a multiple phase CT 
examination including unenhanced images (to allow characterization 
of residual haemorrhagic component), HAP based on a bolus-tracking 
method (for accurate peak arterial enhancement), portal venous phase 
at 60 or 70 seconds, and LP at 120 seconds after iodinated contrast 
injection at a rate of 4 to 5 mL/s. In this study we employed a biphasic 
contrast-enhanced CT protocol, excluding unenhanced and portal 
venous phase scan, to limit the effective dose in cirrhotic patients 
undergoing repeated CT examinations during the imaging follow-up 
with the assumption that the inclusion of only two phases, HAP and LP, 
would achieve comparable diagnostic performance to the conventional 
multiple phase protocol. 
In keeping with our results, a recent study showed that the 80-kV 
CT protocol with the contrast media dose reduced by 50% (300 mgI/
kg) yielded contrast enhancement equivalent to the conventional 120-
kVp protocol with the standard contrast media dose (600 mgI/ml) [16]. 
In our study we maintained roughly the same iodine load per patient 
(450–570 mgI/kg for iodine 400 mgI/ml and 410 – 530 mgI/kg for 
iodine 370 mgI/ml) and the same fractional dose of iodinated contrast 
agent (21-22 mgI/kg/sec) by keeping constant the volume of iodinated 
agent administered for each patient. 
According to our results in a patient population with a BMI in the 
range of 20 - 25, low-dose dual-phase CT at 80kV kV or 100 kV after 
370 mgI/mL or 400 mgI/ml contrast media injection allow to provide 
the maximal radiation dose reduction with a DLP mean value (<800 
mGy*cm) within the diagnostic reference levels for the abdomen 
[17] and with acceptable SNR to monitor the therapeutic outcome 
in cirrhotic patients. Even though the noise level increases at low kV 
(80–100 kV) the SNR remains comparable to conventional 120kV 
CT scan. This was likely due to the higher photon attenuation from 
photoelectric interaction with the K-shell electrons and the higher 
iodine concentration contrast agent (370–400 mgI/mL) used at 80–100 
kV in the present study. Our results are also in keeping with previous 
studies in which low-kV CT scan provided SNR and CNR values 
comparable to 120-kV CT scan [18–20]. Consequently, we believe that 
low-kV CT (80-100 kV) could be employed routinely in patients with 
HCC during the imaging follow-up after loco-regional treatment. 
Our study is limited by its observational nature and the reduced 
patients’ number due to the strict inclusion criteria. In conclusion, 
contrast-enhanced CT at 80-100 KV does not reduce SNR but provides 
effective dose reduction in cirrhotic patients undergoing follow-up 
after thermal ablation and/or TACE. 
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